Capricor Therapeutics joined PPMD for a webinar on November 30, 2017 to discuss the 12-month results from Capricor’s HOPE-Duchenne Clinical Trial, as well as the company’s plans for the HOPE-2 Clinical Trial in the first quarter of 2018, pending regulatory approval.
by: Parent Project Muscular Dystrophy
